Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
TCHP (Docetaxel) Variant #01 | ERBB2 | R 81 743 | 21d | — | — | ~6 | ~R 203 970 PFS proxy · indirect | 1 |
TCHP (Paclitaxel) Variant #01 | ERBB2 | R 80 962 | 21d | — | — | ~9 | ~R 285 906 indirect | — |
THP (Docetaxel) Variant #01 | ERBB2 | R 80 080 | 21d | ~16.5 mo | ~36.2 mo | ~3 | ~R 110 020 PFS proxy · indirect | 8 |
TCHP (Docetaxel, SC Trastuzumab) Variant #01 Partial | ERBB2 | R 67 684 | 21d | — | — | ~6 | ~R 171 166 indirect | — |
THL (Paclitaxel) Variant #02 | ERBB2 | R 46 311 | 28d | — | — | ~3 | ~R 138 933 indirect | — |
Lapatinib and Paclitaxel (TL) Variant #01 | ERBB2 | R 39 513 | 28d | — | ~27.8 mo | ~2 | ~R 79 026 PFS proxy · indirect | 1 |
TCyH (Docetaxel) Variant #01 | ERBB2 | R 35 226 | 21d | — | — | ~13 | ~R 126 847 indirect | — |
Docetaxel and Trastuzumab (TH) Variant #02 | ERBB2 | R 31 039 | 21d | ~12.4 mo | ~26.5 mo | ~4 | ~R 81 980 PFS proxy · indirect | 11 |
Docetaxel and Trastuzumab (TH) and Pyrotinib Variant #01 Partial | ERBB2 | R 16 980 | 21d | ~24.3 mo | — | ~4 | ~R 35 117 PFS proxy · indirect | 1 |
Lapatinib and Trastuzumab Variant #04 | ERBB2 | R 15 652 | 42d | ~2.6 mo | ~14.0 mo | ~3 | ~R 32 897 PFS proxy · indirect | 2 |
Paclitaxel and Trastuzumab (TH) Variant #01 | ERBB2 | R 15 366 | 21d | ~12.9 mo | ~24.0 mo | ~4 | ~R 28 660 PFS proxy · indirect | 10 |
Trastuzumab monotherapy Variant #09 | ERBB2 | R 9 373 | 42d | — | — | ~10 | ~R 51 549 PFS proxy · indirect | 2 |
CVAP Variant #01 | — | R 7 272 | 21d | — | — | ~3 | ~R 7 941 indirect | — |
CVAP (Prednisolone) Variant #01 | — | R 1 095 | 21d | — | — | ~4 | ~R 4 379 indirect | — |
No neoadjuvant therapy Partial | — | — | — | ~26.4 mo | ~37.0 mo | — | — | 12 |
No neoadjuvant therapy Partial | ER | — | — | ~26.4 mo | ~37.0 mo | — | — | 12 |
16 of 16 regimens shown